By Brad Sorensen, CFA

NASDAQ:EVAX

READ THE FULL EVAX RESEARCH REPORT

Evaxion (NASDAQ:EVAX) is a clinical stage company that is making AI useful in the current environment by using the technology to develop new cancer-fighting vaccines. The company notes that it has demonstrated that it can identify, through the company's AI models, novel targets within days, rather than the traditional years it commonly takes with standard drug discovery methods. The use of AI also allows the company to decrease the risk of failure as the technology filters out those results that may result in low efficacy or unacceptable toxicity.

Company management recently released full-year 2024 results that showed the company made tremendous progress during the year, which we’ve written about, and outlined a 2025 plan that is ambitious and exciting for investors. Most importantly, due to capital market actions that we’ve discussed, the company has enough cash to last to mid-2026, great news for investors that may be concerned about dilution.

The company just announced new data for its lead cancer vaccine EVX-01 that is being developed as a treatment for advanced melanoma. The new Phase 2 trial data showed that 80% of EVX-01 vaccine targets triggered a tumor-specific immune response. This is an improvement from the still impressive 71% and 79% hit rates announced previously.

The trend of the data getting better as time goes on is extremely encouraging for the treatment’s prospects and we are looking forward to the full two-year readout of clinical data in the second half of 2025. This builds on the encouraging news that the company is extending its trial of EVX-01 to a third year so that the company can better explore the full potential of the treatment.

Company management also recently noted that the company expects to use its proprietary AI-Immunology to identify two new vaccine candidates for infectious diseases in 2025—further broadening the company’s pipeline and providing more opportunities for patient treatment.

We continue to be excited about the investment opportunities offered by EVAX. In our view, these announcements are the tip of the iceberg of what the AI platforms developed by Evaxion can achieve and positive news will continue to come out as we move forward. We suggest investors investigate EVAX further and consider investing, as we believe the company is at an inflection point that is the start of sustained uptrend.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. 

DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.